Table 2.
Stratification of DLL3 expression in SCLC by demographic and clinical factors, SP347 assay studies (N = 5)
| Author, year | DLL3 expression (definition) | N patients | Age | Sex | Smoking status | Stage |
|---|---|---|---|---|---|---|
| Furuta [17], 2019 | High (≥ 75%) | 44 |
< 65: 38.6% ≥ 65: 61.4% |
Male: 79.5% Female: 20.5% |
Pack-years ≥ 20: 84.1% < 20: 9.1% Unknown: 6.8% |
TNM stage I–II: 79.5% III–IV: 20.5% |
| Low (< 75%) | 49 |
< 65: 26.5% ≥ 65:73.5% |
Male: 75.5% Female: 24.5% |
Pack-years ≥ 20: 77.6% < 20: 14.3% Unknown: 8.2% |
TNM stage I–II: 95.9% III–IV: 4.1% |
|
| p value (univariate; high versus low) | 0.268 | 0.805 | 0.526 | 0.022 | ||
| Kuempers [10], 2021 | High (≥ 50%) | 16 chemo-naïve | Median (IQR): 57.0 (65.0, 88.0) |
Male: 78.6% Female: 21.4% |
NR |
TNM stage < IV: 14.3% IV: 28.6% Missing: 57.1% |
| Low (< 50%) | 14 chemo-naïve | Median (IQR): 67.0 (61.0, 75.0) |
Male: 56.2% Female: 43.8% |
NR |
TNM stage < IV: 12.5% IV: 37.5% Missing: 50.0% |
|
| p value (univariate; high versus low in chemo-naïve) | 0.024 | 0.26 | NR | 1.0 | ||
| High (≥ 50%) | 19 chemo-relapsed | NR | NR | NR | NR | |
| Low (< 50%) | 11 chemo-relapsed | NR | NR | NR | NR | |
| p value (univariate; high versus low in chemo-relapsed) | > 0.05 | > 0.05 | NR | > 0.05 | ||
| Rojo [6], 2020 | Positive (≥ 25%) | 895 |
< 65: 44.5% ≥ 65: 55.2% Missing: 0.3% |
Male: 65.1% Female: 34.9% |
NR |
Limited: 31.1% Extensive: 64.2% Missing: 4.7% |
| Negative (< 24%) | 155 |
< 65: 40.0% ≥ 65: 60.0% Missing: 0% |
Male: 60.6% Female: 39.4% |
NR |
Limited: 36.8% Extensive: 59.4% Missing: 3.9% |
|
| p value (multivariate, positive versusnegative) | NR (p > 0.05 on univariate analyses) | NR (p > 0.05 on univariate analyses) | NR | 0.1995; OR 0.767 (95% CI 0.511, 1.151) | ||
| High positive (≥ 75%) | 719 | NR | NR | NR | NR | |
| p value (multivariate, high positive versus negative + non-high positive) | NR (p > 0.05 on univariate analyses) | NR (p > 0.05 on univariate analyses) | NR | 0.0835; OR 0.752 (95% CI 0.545, 1.039) | ||
| Non-high positive (25–74%) | 176 | NR | NR | NR | NR | |
| p value (multivariate, high positive versus non-high positive) | NR (p > 0.05 on univariate analyses) | 0.0580; OR 1.450 (95% CI: 0.987, 2.129) | NR | 0.1061; OR 1.357 (95% CI: 0.937, 1.965) | ||
| Tendler [25], 2020 | High (undefined) | 38 |
< 70: 34.2% ≥ 70: 65.6% |
Male: 47.4% Female: 52.6% |
NR |
Limited disease: 44.7% Extensive disease: 55.3% |
| Low (undefined) | 8 |
< 70: 50.0% ≥ 70: 50.0% |
Male: 25.0% Female: 75.0% |
NR |
Limited disease: 25.0% Extensive disease: 75.0% |
|
| p value (univariate; high versus low) | < 0.05 | > 0.05 | NR | > 0.05 | ||
| Xie [23], 2019 | High (≥ 50%) | 35 | Median (range): 69.5 (53.2–81.8) |
Male: 34.3% Female: 65.7% |
NR |
TNM stage I: 46.4% II: 10.7% III/IV: 42.9% |
| Low (< 50%) | 9 | Median (range): 71.7 (41.9–88.1) |
Male: 77.8% Female: 22.2% |
NR |
TNM stage I: 28.6% II: 14.3% III/IV: 57.1% |
|
| p value (univariate; high versus low) | 0.49 | 0.03 | NR | 0.73 | ||
Bold values indicate statistical significance (p < 0.05)
NR not reported